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Background: Mirincamycin is a close analog of the drug clindamycin used to treat Plasmodium falciparum blood
stages. The clinical need to treat Plasmodium vivax dormant liver stages and prevent relapse with a drug other than
primaquine led to the evaluation of mirinicamycin against liver stages in animals.
Methods: cis-mirinicamycin and trans-mirinicamycin were evaluated as prophylaxis against early liver stages of
Plasmodium berghei in mice and as antirelapse hypnozoiticides against Plasmodium cynomolgi in the Rhesus
monkey (Macaca mulatta).
Results: Mirincamycin was very effective against early liver stages of P. berghei in mice: both cis and trans
enantiomers were 90-100% causally prophylactic at 3.3 mg/kg/day for 3 days orally. Both cis and trans mirincamycin,
however, failed to kill dormant liver stages (hypnozoites) in the P. cynomolgi infected Rhesus monkey, the only
preclinical hypnozoite model. Mirincamycin enantiomers at 80 mg/kg/day for 7 days orally, a dose that generated
exposures comparable to that seen clinically, did not prevent relapse in any of four monkeys.
Conclusions: Although efficacy against early liver stages of P. berghei was thought to correlate with anti-hypnozoite
activity in primates, for mirincamycin, at least, there was no correlation. The negative P. cynomolgi hypnozoite data
from Rhesus monkeys indicates that mirincamycin is unlikely to have potential as a clinical anti-relapse agent.
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After more than 50 years of neglect, it is recognized that
Plasmodium vivax infection is widespread, can be as se-
vere as Plasmodium falciparum infection, and is a serious
disease [1]. Treatment of P. vivax requires elimination
of the blood stages, the cause of clinical disease, with
standard blood schizonticides, and also elimination of
the dormant hypnozoite stages in the liver to prevent
relapse of blood infection. Primaquine is the only clinical
hypnozoiticide, but its use is limited by hemolysis in
Glucose-6-phosphatase deficient persons.
Clindamycin is a lincosamide antibiotic which in com-
bination with quinine is recommended for the treatment
of P. falciparum blood stages [2]. Mirincamycin is a close* Correspondence: jbe9320457@aol.com
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unless otherwise stated.chemical congener of clindamycin. (Figure 1), in mirinca-
mycin, the nitrogen in the pyrrolidine ring is demethylated
and a pentyl rather than a propyl group is attached to the
4-position. The carbon at the 4-position in the pyrrolidine
ring can exist in either cis or trans configuration, resulting
in either cis-mirincamycin or trans-mirincamycin [3].
The anti-malarial efficacy of mirincamycin was re-
ported in several preclinical models between 1967 and
1972. Against Plasmodium berghei blood stages in mice,
the 100% curative dose was the same as that for the
positive control chloroquine [4]. When P. falciparum
blood stages in Aotus monkeys were treated for seven
days, mirincamycin 10 mg/kg/day was curative, clinda-
mycin 15 mg/kg/day cured only one of three monkeys,
and chloroquine 20 mg/kg/day was not curative [5]. The
superior efficacy of mirincamycin vs clindamycin for
treatment of P. falciparum was reiterated recently whenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Structures of Lincomycin (left), 7-chlorolincomycin [Clindamycin] (middle), and N-demethyl-4'-pentyl-7-chlorolincomycin
[Mirincamycin] (right).
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mers are more active in vitro (IC50 = 3.2 nM and 2.6 nM)
than clindamycin (IC50 = 12 nM) against P. falciparum
clinical isolates from patients in Gabon [6].
Preclinical evaluation of liver hypnozoiticides starts
with determination of prophylactic efficacy against initial
infection of the liver by P. berghei in mice. Although
P. berghei does not have a dormant hypnozoite stage,
it is possible that prophylaxis of initial liver infection
may pertain to elimination of liver hypnozoites. Com-
pounds active in the P. berghei model are then tested
against Plasmodium cynomolgi sporozoite infection in
the Rhesus monkey (Macaca mulatta). The P. cynomolgi
sporozoite Rhesus monkey model is the only preclinical
model in which hypnozoites are consistently generated
and anti-hyponozoite activity can be reasonably evaluated
[7]. Mirincamycin has not been evaluated for causal
prophylaxis vs P. berghei, but Schmidt et al. did investigate
the prophylactic efficacy of mirincamycin in the Rhesus
monkey model [8]. In a complex experiment, mirincamy-
cin was first assessed as causal prophylaxis against initial
liver infection: drug was administered at 40 mg/kg/day for
9 days surrounding sporozoite inoculation. In animals
which failed prophylaxis, the same dose of drug was re-
administered to assess its activity as a blood schizonticide
and a liver hypnozoiticide. Re-administration of mirinca-
mycin (40 mg/kg/day for seven days) cured the blood
stages in all animals and prevented relapse in two of three
animals [8].
Due to the present interest in non-haemolytic
primaquine replacements, mirincamycin was investi-
gated according to the preclinical paradigm as a causal
prophylactic agent against P. berghei in mice followedby anti-hypnozoite activity against P. cynomolgi in Rhesus
monkeys.
Methods
Causal prophylaxis in mice
Female, malaria-naïve, ICR mice were used in these
experiments. On day 0, each mouse was inoculated
intravenously with 100,000 P. berghei ANKA strain
sporozoites contained in 0.1 ml of PBS with 5% bovine
serum albumin. The sporozoites were obtained by dis-
secting the salivary glands of Anopheles dirus mosqui-
toes, which had previously been fed on donor mice
infected with this Plasmodium strain.
Drug was administered to the mice on days -1, 0, and +1
with respect to sporozoite inoculation. Clindamycin and
racemic/cis/trans mirincamycin were obtained from the
Walter Reed Army Institute of Research (WRAIR) drug
repository and dissolved in 0.5% hydroxyethylcellulose:
0.1% Tween 80. Dissolved drug was administered daily
either subcutaneously (SC) or per os (PO). There were 5
animals per drug dose group.
Blood smears were obtained on days 4, 5, 6, 7, 10,
15, 21 and 31 post-sporozoite inoculation to determine
parasitaemia. The day on which parasites were first seen
was the day of patency. If no parasites were seen by day
31, that dose of drug was concluded to be “causally
prophylactic”.
Pharmacokinetics in mice
Cis-mirincamycin and trans-mirincamycin were admin-
istered once SC or PO at a dose of 40 mg/kg to three
male mice. Blood was taken at ¼, ½, 1, 3, 6, 24, 48, and
72 hours for analysis by LC/MS and the values were
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(version 6.1; Pharsight Corp., Mountain View, CA) to
calculate pharmacokinetic parameters.
Radical cure in Rhesus monkeys
Radical cure of P. cynomolgi hypnozoites in Rhesus
monkeys was evaluated in the model classically used by
Schmidt et al. [9] as recently modified [10]. Anopheles
dirus mosquitoes were fed on a Rhesus monkey infected
with P. cynomolgi strain B (bastianellii). Fourteen to
21 days after feeding, the mosquitoes were anesthetized
by chilling on ice and the salivary glands were removed
and lightly ground with a pestle in a solution of normal
saline with 5% bovine serum albumin to free the sporozo-
ites. Following centrifugation, the supernatant was diluted
with the same solution to achieve 1 × 106 sporozoites/ml
ascertained by phase contrast microscopy. The salivary
glands, diluent, and equipment were chilled throughout
this process, and within 30-60 minutes of preparation,
1 ml of inoculum was injected into the saphenous vein of
each test monkey. The monkeys were Macaca mulatta of
Indian origin, adult (2-8 years), 2.5-8 kg, of either gender,
and malaria-naïve or at least 1 yr past previous malaria-
infection. Day 0 was defined as the day of Plasmodium
sporozoite inoculation.
Drugs (cis-mirincamycin, trans-mirincamycin, chloro-
quine (CQ), and primaquine) dissolved in 0.5% hydro-
xyethylcellulose: 0.1% Tween 80 were administered to
the animals daily PO via a nasogastric tube.
When parasitaemia was >5,000/mm3, monkeys were
randomly assigned to chloroquine PO (10 mg/kg/day ×
7 days) or to one of the eight experimental groups con-
sisting of mirincamycin concurrent with chloroquine.
Chloroquine, which has no direct effect on liver stages,
is administered to eliminate blood stages and thus serves
as a negative control in comparison with groups given
anti-relapse drugs concurrently with CQ. The experi-
mental groups received either cis-mirincamycin PO
(20, 40, or 80 mg/kg/day), trans-mirincamycin PO (20,
40, or 80 mg/kg/day), cis-mirincamycin intravenously
(IV) (20 mg/kg/day), or trans-mirincamycin IV (20 mg/
kg/day). The IV 20 mg/kg/day dose was reduced to 5 mg/
kg/day beginning on day 3 after animals developed an
acute haemolytic reaction. Since these were dose-ranging
experiments, the number of monkeys per group was lim-
ited to two.
Efficacy was evaluated by blood smears in which para-
sitaemia was assessed daily from day 7 post-sporozoite
inoculation through day 21, then three times per week
for 4 weeks and two times per week until parasitaemic
or until day 100 post drug treatment. The day of patency
was defined as the first day of slide-confirmed parasit-
aemia. Radical cure was defined as being without relapsing
parasitaemia for 100 days post drug treatment.Pharmacokinetics in Rhesus
Blood was taken at 1, 2, 4, 6, 24, 48, 72, 168, and 336 hr
after the 7th dose of drug in the above efficacy experiments.
The concentration of drug in Rhesus monkey blood was
determined by LC/MS as per Khemawoot et al. [3]
Animal use
The USAMC-AFRIMS Institutional Animal care and
Use Committee (IACUC) and the Animal Use Review
Division, U.S. Army Medical Research and Materiel
Command reviewed and approved these studies. Animals
were maintained in accordance with established principles
under the Guide for the Care and Use of Laboratory
Animals [NRC 1996]. The USAMC-AFRIMS animal care
and use program has been accredited by Association for
Assessment and Accreditation for Laboratory Animal
Care (AAALAC) International.
Results
Causal prophylaxis in mice
Mirincamycin was much more active as a causal prophy-
lactic agent than the lincosamide congeners clindamycin
and lincomycin in the P. berghei-infected mouse model.
When drugs were administered SC, racemic mirincamycin
at 3.3 mg/kg/day (MKD) was 100% causally prophylactic
in experiment 180 (Table 1), whereas clindamycin pro-
tected 3 of 5 mice at 40 MKD (Table 1: experiment 179)
and lincomycin was inactive at that dose (Table 1: experi-
ment 200). The causal efficacy of cis and trans mirincamy-
cin administered SC was compared at 1.1 MKD and lower
doses. At 1.1 MKD, the cis-enantiomer with five of five
cures was slightly more active than the trans-enantiomer
with three of five cures at this dose (Table 1: experiments
179, 180).
PO dosing was investigated in experiments 206, 208,
and 234 (Table 1). The enantiomers were approximately
equally active (10 of 10 mice protected by the cis-isomer
and 9 of 10 mice protected by the trans-isomer at 3.3
MKD) although an anomalous finding was that only
three of five mice were protected by the cis-isomer at 10
MKD in experiment 208.
Pharmacokinetics in mice
After 40 mg/kg once, AUC (0-infinity) was 13,952 ng*h/
ml for cis-mirincamycin delivered SC, 7,063 ng*h/ml
for cis-mirincamycin administered PO, 12,827 ng*h/ml
for trans-mirincamycin delivered SC, and 3,093 ng*h/
ml for trans-mirincamycin administered PO. Bioavailability
was, therefore, 52% for the cis isomer and 23% for the
trans isomer.
Radical cure in Rhesus monkeys
Although cis-mirincamycin and trans-mirincamycin were
given from 20 MKD to 80 MKD orally for 7 days, or
Table 1 Mouse causal prophylaxis experiments
DRUG (SC or PO) Dose (mg/kg/day) No. inoculated No. 100% protected Day of parasitaemia Exp#
None 0.00 35 0 4-to-5 179
Clindamycin (SC) 10.00 5 0 6-to-7 179
40.00 5 3 10,10 179
Mirincamycin (racemate: 65% trans) (SC) 1.10 5 3 10,10 180
3.30 5 5 na 180
cis-Mirincamycin (SC) 1.10 5 5 na 180
3.30 5 5 na 180
trans-Mirincamycin (SC) 1.10 5 3 10,10 179
3.30 5 5 na 179
Lincomycin (SC) 1.1-to-40 5 0 4-to-5 200
cis-Mirincamycin (SC) 0.14 5 0 5-to-6 204
0.28 5 0 6-to-8 204
0.55 5 3 7,9 204
1.10 5 4 7 204
cis-Mirincamycin (SC) 0.14 5 0 4-to-6 205
0.28 5 0 6-to-8 205
0.55 5 0 7-to-10 205
1.10 5 3 10,10 205
Mirincamycin (racemate: 65% trans) (PO) 1.10 5 0 7-to-9 208
3.30 5 3 7-to-8 208
10.00 5 5 na 208
40.00 5 5 na 208
cis-Mirincamycin (PO) 1.10 5 0 7-to-8 208
3.30 5 5 na 208
10.00 5 3 7-to-8 208
40.00 5 5 na 208
cis-Mirincamycin (PO) 2 5 1 7–11 234
3.3 5 5 na 234
10 5 5 na 234
trans-Mirincamycin (PO) 1.10 5 0 7 206
3.30 5 5 na 206
10.00 5 5 na 206
40.00 5 5 na 206
trans-Mirincamycin (PO) 2 5 2 7–8 234
3.3 5 4 10 234
10 5 5 na 234
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days, no animal demonstrated radical cure (Table 2).
The two control animals showed relapse within 11 to
14 days post-treatment. Except for one of the cis-mir-
incamycin 40 mg/kg animals, which is viewed as anoutlier, all doses up to 80 MKD delayed relapse by at
most 44 of the 100 days of follow up. Higher oral
doses at least of trans-mirincamycin could not be
given, as loose stools were seen on each day of drug
administration in the 40 MKD and 80 MKD groups.
Table 2 Rhesus monkey anti-hypnozoite experiments









on day 7 [mean]
Treatment of initial parasitaemia
Chloroquine* 0 0//2 11, 14 na na
cis-mirincamycin (PO) + CQ* 20 0//2 21, 21 8, 8 1681
cis-mirincamycin (PO) + CQ* 40 0//2 34, 75 21, 62 7125
cis-mirincamycin (PO) + CQ* 80 0//2 27, 33 14, 20 8878
trans-mirincamycin (PO) + CQ* 20 0//2 18, 18 5, 5 1343
trans-mirincamycin (PO) + CQ* 40 0//2 18, 21 5, 8 4056
trans-mirincamycin (PO) + CQ* 80 0//2 29, 44 16, 31 9080
cis-mirincamycin (IV) + CQ* 20 then 5 0//2 18, 18 5, 5 1922
trans-mirincamycin (IV) + CQ* 20 then 5 0//2 18, 21 5, 8 1789
*Chloroquine (CQ) dose was 10 mg/kg/day for 7 days per os (PO).
**Drugs given daily for 7 days.
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AUC (0-infinity) increased from approximately 1,500 ng*h/
mL in animals receiving 20 MKD PO to approximately
9,000 ng*h/mL in animals receiving 80 MKD PO (Table 2).
Bioavailability based on comparison of AUCs in the
5 MKD IV groups (Table 2) to the 20 MKD PO
groups was 23% for cis-mirincamycin and 19% for
trans-mirincamycin.
Data in healthy Rhesus monkeys administered 20 MKD
PO of each isomer was recently published [3]. The ratio of
AUCs in infected Rhesus monkeys in the present work
compared to healthy Rhesus monkeys in Khemawoot
et al. [3] is 66% for cis-mirinicamycin and 50% for
trans-mirincamycin.
Discussion
Mirincamycin was an effective causal prophylactic agent
against P. berghei in mice. Both cis and trans enantio-
mers at a dose of 3.3 mg/kg/day for three days protected
90-100% of mice. Myrincamycin mouse causal prophy-
lactic results were, however, unpredictive for efficacy
against P. cynomolgi hypnozoites in Rhesus monkeys.
Even mirincamycin doses of 80 mg/kg/day for seven
days failed to protect a single monkey, and the day of
relapse was prolonged at most by 30 days over chloro-
quine controls.
Pharmacokinetic analysis showed that drug exposure
in Rhesus monkeys was higher than in mice and com-
parable to man. After 80 mg/kg/day in Rhesus monkeys,
AUC was approximately 9,000 ng*h/ml. After 40 mg/kg
in mice, AUC for the two enantiomers was approximately
3,000-7,000 ng*h/ml and AUC following the effective dose
of 3.3 mg/kg must have been a small fraction of those
values. In normal human volunteers following the 1st
and 29th administration of the highest dose adminis-
tered (375 mg), mean AUC was 3,725 ng*h/ml and
18,117 ng*h/ml, respectively [11]. The lack of efficacy inRhesus monkeys at exposures higher than that effective
in mice and comparable to that achieved clinically indi-
cates that the negative Rhesus monkey data is not due
to under dosing.
The failure of mirincamycin at 80 MKD in 4 of 4 mon-
keys in our hands contrasts to the success of the drug at
40 MKD in 2 of 3 monkeys in earlier work by Schmidt
et al. [8]. Schmidt’s experimental design was to re-
administer drug for anti-hypnozoite activity to parasites
which had survived exposure to the same drug in causal
prophylactic experiments. The parasites may have been
attenuated by their prior exposure and be overly suscep-
tible to the second administration of drug. The present
anti-hypnozoite experiments evaluated efficacy when, as
per the clinic, the hypnozoiticide had not previously
been given to the host.
Conclusion
Although mirincamycin as per clindamycin may well
have value as a blood schizonticide, present P. cynomolgi
Rhesus monkey experiments indicate that mirincamycin
does not have value as an anti-relapse agent.
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